Celcuity (CELC) Stock Analysis

What Celcuity does

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Key metrics

ETFs linked to CELC

Broad-market and Healthcare sector ETFs an investor holding Celcuity is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CELC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Celcuity?

Celcuity trades under the ticker CELC on NASDAQ.

Which exchange is CELC listed on?

CELC is listed on NASDAQ.

What sector does Celcuity operate in?

Celcuity is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CELC in a portfolio?

PortView shows CELC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.